1220165-54-7

Usage

Uses

Used in Pharmaceutical Research:
4-bromo-1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine is used as a research compound for the development of new drugs. Its unique structure and properties make it a valuable building block in the synthesis of biologically active molecules, contributing to the discovery of novel therapeutic agents.
Used in Drug Development:
In the drug development industry, 4-bromo-1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine is utilized as a key intermediate in the synthesis of potential drug candidates. Its presence in these molecules can enhance their pharmacological properties, leading to the creation of more effective treatments for various diseases and conditions.
Used in Therapeutic Applications:
4-bromo-1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine is being studied for its potential therapeutic effects in the treatment of various diseases and conditions. Its unique chemical structure allows it to interact with biological targets, offering new avenues for the development of innovative treatments.
Used in Chemical Industry:
In the chemical industry, 4-bromo-1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine is employed as a versatile intermediate for the synthesis of a wide range of chemical products. Its ability to form various derivatives makes it a valuable component in the creation of specialty chemicals and materials with diverse applications.

Upstream product

• 70201-42-2 3,5-dibromopyridine-4-carboxaldehyde 
• 371-14-2 4-fluorophenylhydrazine 
• 1220165-45-6 N-[1-(3,5-dibromopyridin-4-yl)-meth-(E)-ylidene]-N'-(4-fluorophenyl)-hydrazine 
• 823-85-8 4-fluorophenyhydrazine hydrochloride 

Downstream Products

• 1220025-85-3 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid 3-trifluoromethyl-benzylamide 
• 1220165-87-6 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid ethyl ester 
• 1295298-36-0 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid [1-(3-trifluoromethyl-phenyl)cyclopropyl]amide 
• 1295298-09-7 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid [1-(5-methanesulfonyl-furan-2-yl)cyclopropyl]amide 
• 1295298-11-1 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid [1-(2-bromopyridin-4-yl)cyclopropyl]amide 
• 1295298-14-4 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid (1-1,3,4-thiadiazol-2-yl-cyclopropyl)amide 
• 1295298-15-5 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid [1-(3-bromophenyl)cyclopropyl]amide 
• 1345828-31-0 1-(4-fluoro-phenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid (5-methanesulfonyl-2,4-dimethyl-phenyl)-amide 
• 1220026-26-5 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid (2-methanesulfonyl-pyridin-4-ylmethyl)-amide 

Relevant academic research and scientific papers

Identification of novel azaindazole CCR1 antagonist clinical candidates

Exploring various cyclization strategies, using a submicromolar pyrazole HTS screening hit 6 as a starting point, a novel indazole based CCR1 antagonist core was discovered. This report presents the design and SAR of CCR1 indazole and azaindazole antagonists leading to the identification of three development compounds, including 19e that was advanced to early clinical trials.

INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS

Diclosed are CCRl receptor antagonists of the formula (I), wherein X is nitrogen or, C-R2; Ar1 is carbocycle, heteroaryl or heterocyclyl each optionally substituted by one to three Ra; Ar2 is carbocycle, heteroaryl or heterocyclyl, each optionally substituted by one to three Rb; Cyclic G is carbocycle, or heterocyclyl each optionally substituted by one to two R8; R1 is hydrogen, C1-6 alkyl or C 1-6 alkoxyC1-6 alkyl. Also disclosed are compositions, methods of making and using compounds of the formula (I).

AZAINDAZOLE AMIDE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS

Disclosed are CCR1 inhibitor compounds of the formula (I): which are useful in the treatment of autoimmune and other diseases. Also disclosed a pharmaceutical compositions containing the same, and methods of making and using same.

AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.